Literature DB >> 24574363

HFE-associated hereditary hemochromatosis: overview of genetics and clinical implications for nurse practitioners in primary care settings.

Donna Emanuele1, Ivy Tuason, Quannetta T Edwards.   

Abstract

PURPOSE: HFE-hemochromatosis is one of the most common genetic disorders in the United States among Caucasians of Northern European ancestry. The purpose of this article is to discuss HFE-associated hereditary hemochromatosis (HH), including the genetics, pathophysiology, phenotype and genotype, diagnostics, and management utilizing a case-based format as an exemplar. DATA SOURCES: Online genetic resources; professional guidelines; review; and scientific articles.
CONCLUSION: HFE-HH is an autosomal recessive disorder and two major genes C282Y and H63D are associated with HH (iron overload) susceptibility particularly C282Y/C282Y mutations. It has a variable penetrance and expression. Individuals who develop iron overload may develop broad symptoms, including joint discomfort, fatigue, decreased libido, and abdominal pain; and if left untreated, HFE-HH has the potential of developing end-organ disease including liver fibrosis, cirrhosis, and cancer; cardiac arrhythmias or heart failure; and diabetes. Suspicion of the disorder begins with personal and family history, transferrin saturation, and ferritin levels, and if high, genotyping to confirm the disorder. Management consists of correcting iron overload to prevent/delay end-organ damage often consisting of intermittent phlebotomy. IMPLICATIONS FOR PRACTICE: Knowledge of HFE-HH is essential so that nurse practitioners can identify individuals at risk and to provide appropriate management of care and referral. ©2014 The Author(s) ©2014 American Association of Nurse Practitioners.

Entities:  

Keywords:  Genetics; digestive system; liver; nurse practitioners; primary care

Mesh:

Year:  2014        PMID: 24574363     DOI: 10.1002/2327-6924.12106

Source DB:  PubMed          Journal:  J Am Assoc Nurse Pract        ISSN: 2327-6886            Impact factor:   1.165


  5 in total

1.  Effect of the Hemochromatosis Mutations on Iron Overload among the Indian β Thalassemia Carriers.

Authors:  Anita H Nadkarni; Aradhana A Singh; Stacy Colaco; Priya Hariharan; Roshan B Colah; Kanjaksha Ghosh
Journal:  J Clin Lab Anal       Date:  2016-08-26       Impact factor: 2.352

Review 2.  Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities.

Authors:  Caiguo Zhang; Fan Zhang
Journal:  Protein Cell       Date:  2014-12-06       Impact factor: 14.870

3.  Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis.

Authors:  Annick Vanclooster; Hub Wollersheim; Kris Vanhaecht; Dorine Swinkels; Bert Aertgeerts; David Cassiman
Journal:  BMC Health Serv Res       Date:  2016-10-13       Impact factor: 2.655

4.  Hemochromatosis drives acute lethal intestinal responses to hyperyersiniabactin-producing Yersinia pseudotuberculosis.

Authors:  Shreya Das; Mohd Saqib; Ryan C Meng; Sridar V Chittur; Ziqiang Guan; Fengyi Wan; Wei Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-11       Impact factor: 12.779

5.  Acute Free-Iron Exposure Does Not Explain the Impaired Haemorheology Associated with Haemochromatosis.

Authors:  Antony P McNamee; Surendran Sabapathy; Indu Singh; Jarod Horobin; Janelle Guerrero; Michael J Simmonds
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.